<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Nektar Therapeutics</title>
	<atom:link href="http://www.stockbloghub.com/tag/nektar-therapeutics/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AIB) Company News for May 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393</link>
		<comments>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393#comments</comments>
		<pubDate>Wed, 18 May 2011 15:20:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Foreign Money Center Banks]]></category>
		<category><![CDATA[AIB]]></category>
		<category><![CDATA[Allied Irish Banks plc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[eLong Inc]]></category>
		<category><![CDATA[Fairpoint Communications Inc.]]></category>
		<category><![CDATA[FRP]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[LINE]]></category>
		<category><![CDATA[Linn Energy Llc]]></category>
		<category><![CDATA[LONG]]></category>
		<category><![CDATA[MAKO]]></category>
		<category><![CDATA[MAKO Surgical Corporation]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[ONCOLYTICS BIOTECH]]></category>
		<category><![CDATA[ONCY]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74393</guid>
		<description><![CDATA[•    Dell Inc. (NASDAQ:DELL) reported Q1 EPS of $0.55, higher than the Zacks Consensus Estimate of $0.43 per share. Revenue for the quarter edged up 1% year-over-year to $15.02 billion, falling short of the Zacks Consensus Estimate of $15.457 billion •    Share prices of US listed Allied Irish Banks, PLC. (NYSE:AIB) rose 13.33% to close at $3.06 after the banking company unveiled a new structure and top management team •    Leerink Swann initiated coverage on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) with an &#8220;Outperform&#8221; rating and a valuation call of $12 to $14 per share •    Share prices of elong, Inc. (NASDAQ:LONG) increased 56.72% on news that China‘s Tencent Holdings has bought a 16% stake in the company for $84.4 million •    Shares of FairPoint Communications, Inc. (NASDAQ:FRP) fell more ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/aib-company-news-for-may-18-2011-corporate-summary/74393/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Company News for January 20, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/01/21/abt-company-news-for-january-20-2011-corporate-summary/65455</link>
		<comments>http://www.stockbloghub.com/2011/01/21/abt-company-news-for-january-20-2011-corporate-summary/65455#comments</comments>
		<pubDate>Fri, 21 Jan 2011 17:24:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADTN]]></category>
		<category><![CDATA[ADTRAN Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[X]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65455</guid>
		<description><![CDATA[• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night • Adtran Inc (NASDAQ:ADTN) increased 6.56% to end at $42.25 after the company posted an  increased sales figures for the fourth quarter that came in above expectations • Shares of Northern Trust Corp (NASDAQ:NTRS) had fallen by 5.6% while State Street Corp (NYSE:STT) fell 4.12% • In other news, share prices of Janus Capital Group Inc (NYSE:JNS) fell by 4.36%, after Stifel Nicolaus downgraded from hold to buy rating • A change of rating by Deutsche Bank from buy to hold has left shares prices to fall of United States Steel Corps (NYSE:X) at $52.09, a decline of 5.9% • In other news, DepoMed Inc’s (NASDAQ:DEPO) fell considerably to $5.66 after a licensing dispute between ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/21/abt-company-news-for-january-20-2011-corporate-summary/65455/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIGA) These Healthcare Stocks Are Ready to Move Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553</link>
		<comments>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553#comments</comments>
		<pubDate>Fri, 07 Jan 2011 18:11:43 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[CGEN]]></category>
		<category><![CDATA[Compugen Limited]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SIGA]]></category>
		<category><![CDATA[SIGA Technologies Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64553</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, January 5, 2011: Issue #1421 Once again, I’ve secured my golden ticket to the most important healthcare event of the year. In the past, I’ve described the JP Morgan Healthcare Conference as the Super Bowl of the healthcare investing world. That’s no exaggeration either, as industry executives and investors jet in from all over the world to attend. And with hotels, restaurants and even the 37 Starbucks in Union Square packed with people looking for and providing information, even those without an invitation still hit San Francisco just to be near the action. It’s the place to get the latest news on drug development, research funding, and the companies that could be on the cusp of greatness. And for the past few ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/07/siga-these-healthcare-stocks-are-ready-to-move-next-week/64553/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Nektar Therapeutics Announces Preliminary Data</title>
		<link>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879</link>
		<comments>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879#comments</comments>
		<pubDate>Thu, 14 Jan 2010 00:31:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24879</guid>
		<description><![CDATA[Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been observed that the drug, tested in women with platinum-resistant ovarian cancer, achieved an overall response rate of 32% and 35% in two dosage schedules – once every 14 days and once every 21 days. Common side effects such as diarrhea and neutropenia were observed during the trial. Nektar announced that enrollment of patients ? 71 in all ? in the trial has been completed. Apart from ovarian cancer, NKTR-102 is also being studied in two other mid-stage trials for the treatment of metastatic breast cancer and second-line colorectal cancer. We believe favorable data from the phase II trial could enable Nektar to enter into suitable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year</title>
		<link>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311</link>
		<comments>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311#comments</comments>
		<pubDate>Thu, 07 Jan 2010 00:12:43 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24311</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 6, 2010: Issue #1169 Now that we’re into the first week of 2010, let’s talk about the Super Bowl. But not the one in Miami, featuring a bunch of guys with pads and helmets. I’m talking about the healthcare sector’s version of the Super Bowl, taking place on the other side of the United States next week. On Sunday, I’ll be boarding a plane and escaping from the frozen tundra that is South Florida these days (seriously, 29 degrees last night) and on my way to San Francisco for the J.P. Morgan Healthcare Conference. And just like the Super Bowl, tickets for the conference are extremely hard to get. It’s the most important healthcare conference of the year, and roughly 14,000 investors and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Beats Expectations and Raises</title>
		<link>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500</link>
		<comments>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:31:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20500</guid>
		<description><![CDATA[AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/azn-astrazeneca-beats-expectations-and-raises/20500/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) The F.I.R.S.T. System: Searching For the “Holy Grail” of Investing</title>
		<link>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084</link>
		<comments>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:37:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19084</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, October 28, 2009: Issue #1125 When it comes to investing, how do you find the “Holy Grail?” Does it even exist? Over my 19 years of stock market experience, I’ve searched high and low for the answers. One of my first steps was to plow into technical analysis. I studied everything I could, believing that charts could predict a stock’s direction. I even became a trained technician, finishing two out of the three exams required to be a Chartered Market Technician. I never took the third. While I believe technical analysis is useful, it didn’t provide the answers I was looking for. In 2005, Avalon Research Group hired me as a fundamental analyst. While at Avalon, I worked with two of the greatest contrarians ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Nektar Therapeutics Presents Favorable Phase II Trial Data</title>
		<link>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491</link>
		<comments>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491#comments</comments>
		<pubDate>Tue, 13 Oct 2009 19:35:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17491</guid>
		<description><![CDATA[Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management&#8217;s 20th Annual Clinical Meeting in Phoenix, AZ. The drug met the primary endpoint of increase in spontaneous bowel movement over the baseline period along with no reduction of opioid-mediated analgesia in any dose groups. In addition, NKTR-118 was well tolerated, the common side effects being dose-dependent gastrointestinal-related effects. In September, AstraZeneca (AZN) had entered into a licensing deal with Nektar Therapeutics for two of its pipeline candidates, NKTR-118 and NKTR-119. While the former is a phase II trial candidate, the latter, in its early stage of development, is intended to treat pain without constipation as a side effect. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca and Nektar Therapeutics Deal to Add Value</title>
		<link>http://www.stockbloghub.com/2009/10/03/azn-astrazeneca-and-nektar-therapeutics-deal-to-add-value/16545</link>
		<comments>http://www.stockbloghub.com/2009/10/03/azn-astrazeneca-and-nektar-therapeutics-deal-to-add-value/16545#comments</comments>
		<pubDate>Sat, 03 Oct 2009 21:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16545</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront payment of $125 million for both the candidates. In addition, for NKTR-118, Nektar has the potential to receive $235 million of milestone payments on achieving certain regulatory milestones, as well as additional tiered sales milestone payments of up to $375 million if the drug succeeds in recording strong sales. The company will also receive double-digit royalty payments on global sales of the drug. For NKTR-119, Nektar is also supposed to receive milestone and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/azn-astrazeneca-and-nektar-therapeutics-deal-to-add-value/16545/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Signs Licensing Deal With Nektar Therapeutics</title>
		<link>http://www.stockbloghub.com/2009/09/22/azn-astrazeneca-signs-licensing-deal-with-nektar-therapeutics/15824</link>
		<comments>http://www.stockbloghub.com/2009/09/22/azn-astrazeneca-signs-licensing-deal-with-nektar-therapeutics/15824#comments</comments>
		<pubDate>Tue, 22 Sep 2009 20:50:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15824</guid>
		<description><![CDATA[Yesterday, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront payment of $125 million for both the candidates. In addition, for NKTR-118, Nektar has the potential to receive $235 million of milestone payments on achieving certain regulatory milestones, as well as additional tiered sales milestone payments of up to $375 million if the drug succeeds in recording strong sales. The company will also receive double-digit royalty payments on global sales of the drug. For NKTR-119, Nektar is also supposed to receive milestone and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/22/azn-astrazeneca-signs-licensing-deal-with-nektar-therapeutics/15824/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

